AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

AbbVie (NYSE:ABBV) just scored a big win for its next-generation arthritis drug. The company said Monday that Rinvoq ...

(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...

US FDA approves updated indication statement for AbbVie’s Rinvoq for the treatment of inflammatory bowel disease: North Chicago, Illinois Wednesday, October 15, 2025, 12:00 Hrs ...

ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's ...

Tuesday, October 21, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research ...

Discover why Schwab U.S. Dividend Equity ETF™ is a top choice for stable income, strong yields, and diversification. Click ...

AbbVie said its Rinvoq showed superiority over the company’s previous bestselling drug Humira in a head-to-head trial. Results showed that 43% of patients compared to 22% of patients on Humira ...

A Selkirk woman living with a disability says she’s spent more than a year fighting Manitoba’s income support system over ...